Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Current Deferred Revenue: 2023

Historic Current Deferred Revenue for BioLineRx (BLRX) over the last 1 years, with Dec 2023 value amounting to $13.0 million.

  • BioLineRx's Current Deferred Revenue was N/A to $2.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was $2.3 million, marking a year-over-year change of. This contributed to the annual value of $13.0 million for FY2023, which is N/A change from last year.
  • According to the latest figures from FY2023, BioLineRx's Current Deferred Revenue is $13.0 million.
  • Over the past 5 years, BioLineRx's Current Deferred Revenue peaked at $13.0 million during FY2023, and registered a low of $13.0 million during FY2023.
  • For the 1-year period, BioLineRx's Current Deferred Revenue averaged around $13.0 million, with its median value being $13.0 million (2023).